PharmAust completes phase 1/2 Motor Neurone Disease clinical trial

PharmAust Limited (ASX: PAA) announced that it has successfully completed its first unit of six patients in its Phase 1/2 clinical trial of its lead drug candidate, monepantel (MPL) in Motor Neurone Disease/Amyotrophic Lateral Sclerosis. On 01 December 2022, the company announced the completion of patient recruitment for treatment level 1; PharmAust has now successfully completed the day 29 dosing of the final patient in the first cohort.

The company confirmed in its preclinical programs that MPL has the potential to activate molecular pathways relevant to the treatment of Motor Neurone Disease. MPL could potentially reduce the rate of degeneration and loss of motor neurons in the brainstem's anterior horns and motor nuclei. With success in the clinical trial, the company hopes that in due course, MPL could get orphan drug designation by the FDA for the indication of motor neurone disease.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com